INSIGHTS ON DRUG DEVELOPMENT

• Ask Us Anything: Päivi Tolstoy On The Future Of API Manufacturing

  Päivi Tolstoy, Manager of Process Development at Cambrex Karlskoga, on why sustainability is the trend to watch in API manufacturing — and why the real question is how few steps it takes to build a complex molecule.

• Benchmarking Filtration Performance Of TFF Cassettes

  Optimize your protein purification workflow with tangential flow filtration by comparing membrane performance and exploring how protein concentration impacts flux and MWCO selection in lab-scale systems.

• Mobile Minor Process Explanation

  Dr. Jordan Potts explains how the Mobile Minor spray dryer works and outlines its role in spray drying and particle engineering research applications.

• What Are ATMPs And Why Do They Matter?

  Delves into the evolution of Advanced Therapy Medicinal Products (ATMPs), exploring their complex development, revolutionary potential in treating diseases, and the intricacies of cell and gene therapies.

• Integrated Stability Workflows That Reduce Manual Data Handling

  5/28/2026

  Integrated accelerated stability workflows reduce manual data handling while improving confidence in shelf‑life predictions. Help your teams move faster with fewer experimental demands.

• Advances In Custom Medium Development: The Multi-Omics Difference

  6/9/2025

  Spent media analysis continues to be an essential part of many media development workflows. Newer techniques, however, using state-of-the-art analytical technology, are becoming more popular.

• Cell Retention Technology And Specialized Cell Culture Media

  8/11/2025

  Explore how perfusion technology is transforming upstream bioprocessing by boosting productivity, reducing costs, and enabling process intensification while overcoming cell retention challenges.

• Amorphous Solids: Implications For Solubility And Stability

  5/6/2026

  Amorphous solids can enhance drug solubility and bioavailability but introduce stability risks, making careful characterization and control essential for successful pharmaceutical development and manufacturing.

• Patented Process For Intermediates Useful For Etrasimod Arginine

  3/13/2026

  Explore how rethinking the synthetic strategy for Etrasimod can overcome the limitations of legacy routes, enabling more efficient chirality control, improved scalability, and more practical industrial API production.